Ali, M. Sanni
Ernst, Martin
Robinson, Danielle E.
Caskey, Fergus
Arden, Nigel K.
Ben-Shlomo, Yoav
Nybo, Mads
Rubin, Katrine H.
Judge, Andrew
Cooper, Cyrus
Javaid, M. K.
Hermann, Anne P.
Prieto-Alhambra, Daniel
Article History
Received: 21 August 2019
Accepted: 30 April 2020
First Online: 1 June 2020
Change Date: 17 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11657-021-01001-9
Compliance with ethical standards
: The study was approved by the Data Protection Agency (OUH 15/37999) and by Statistics Denmark (ref. 705079). All statistical analyses were done on de-identified patient data merged at Statistics Denmark.
: NK Arden reports personal fees from Flexion, Freshfields, Janssen, Merck and Regeneron. C Cooper reports lecture fees and honoraria from the Alliance for Better Bone Health Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. A Judge is a subpanel member of the NIHR PGfAR, has received consultancy fees from Freshfields Bruckhaus Deringer and has held advisory board positions (which involved receipt of fees) at Anthera Pharmaceuticals, INC. MK Javaid reports research support and speaker fees from Amgen. D Prieto-Alhambra reports research grants from UCB, Amgen and Les Laboratoires Servier and (not personal) speaker and consultancy fees from UCB and Amgen. D Prieto-Alhambra is a member of the NIHR HTA CET panel since November 2017. DE Robinson, MS Ali, KRubin, M Ernst, P Hermann, M Nybo, Y Ben-Shlomo and F Caskey have nothing to disclose. The views expressed are those of the authors and not necessarily those of the NHS, NIHR or Department of Health.